Scientists report new process for producing potentially safer form of acetaminophen

NewsGuard 100/100 Score

Scientists in Louisiana are reporting development of a process for producing large batches of a new and potentially safer form of acetaminophen, the widely used pain-reliever now the source of growing concern over its potentially toxic effects on the liver.

Their study, which could speed development of a next-generation pain-reliever, is scheduled for the July 17 issue of ACS' Organic Process Research & Development, a bi-monthly journal.

In June, an advisory panel of the U. S. Food and Drug Administration recommended banning certain prescription pain relievers containing acetaminophen because of the drug's potential to cause liver damage when used in high doses. Mark Trudell and colleagues note in the study that scientists recently discovered a new form of acetaminophen that has similar potency to the original drug with a lower risk of liver toxicity. But until now, scientists have had difficulty producing this substance in quantities suitable for industrial scale-up.

The researchers describe a simple, efficient method for producing the new pain-reliever using only a few starting materials and a short series of chemical reactions. In laboratory studies, they used the new method to produce multigram quantities of the substance with 99 percent purity. The scientists point out that the new process can be performed on a much larger production level if needed.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Depression linked to chronic pain: Variability shown across patient characteristics